echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Albumin paclitaxel can be used as the standard treatment option for patients with advanced NSCLC; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News

    Albumin paclitaxel can be used as the standard treatment option for patients with advanced NSCLC; PD-1/CTLA-4 dual antibody was approved to carry out a phase III clinical trial for the first-line treatment of advanced cervical cancer|Tumor News

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    *Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain) Key points: JTO: After treatment of advanced NSCLC, the OS of albumin paclitaxel treatment is not inferior to docetaxel Lancet Gastroenterol Hepatol: LSD can safely and effectively treat the pancreas or ampulla Peripheral Tumor Gastroenterology: Gene and epigenetic characteristics of inflammatory bowel disease-related colorectal cancer.
    New drug: Cadonilimab was approved for first-line treatment of advanced cervical cancer.
    Global Phase III clinical trial.
    New drug: the first EGFR exon 20 insertion targeted drug TAK -788 received FDA priority review 01JTO: After the treatment of advanced NSCLC, the OS of albumin paclitaxel treatment is not inferior to docetaxel.
    Recently, the Journal of Thoracic Oncology (JTO) published a III clinical study online, which showed that the treatment of albumin paclitaxel was effective The overall survival of treated advanced non-small cell lung cancer (NSCLC) is not inferior to docetaxel.

    Article release screenshots This randomized, open-label, non-inferiority phase III study included a total of 503 patients with advanced NSCLC who were previously treated with chemotherapy, and received docetaxel (60mg/m2, every 21st day) at a 1:1 ratio.
    1 day administration) or albumin paclitaxel (100mg/m2, administration every 21 days on the first 1, 8, 15) treatment.

    The primary endpoint is overall survival (OS).

    The median OS of 252 patients treated with albumin and paclitaxel was 16.
    2 months, and the median OS of 251 patients treated with docetaxel was 13.
    6 months.

    The median progression-free survival of the albumin paclitaxel group and the docetaxel group were 4.
    2 months and 3.
    4 months, respectively (P=0.
    0042), and the objective response rates were 29.
    9% and 15.
    4% (P=0.
    0002), respectively.

    Adverse events of grade ≥3 in the albumin paclitaxel group and docetaxel group included neutropenic fever (5 cases vs.
    55 cases) and peripheral sensory nerve abnormalities (24 cases vs.
    2 cases).

    The above results indicate that in the treated patients with advanced NSCLC, the overall survival of patients treated with albumin paclitaxel is not inferior to that of docetaxel treatment.

    Albumin paclitaxel can be considered as the standard treatment option for such patients.

    02Lancet Gastroenterol Hepatol: LSD can safely and effectively treat pancreatic or periampullary tumors.
    Recently, a multicenter randomized controlled study published online by The Lancet Gastroenterology&Hepatology showed that for pancreatic or periampullary tumors, laparoscopic pancreaticoduodenectomy (LSD) is similar in safety and effectiveness to open pancreaticoduodenectomy (OPD).

    A screenshot of the article release.
    The study included 656 18-75-year-old patients with benign, precancerous or malignant pancreatic or periampullary tumors and eligible for pancreaticoduodenectomy.
    They were randomly assigned to the LPD group at a ratio of 1:1 (N=328) and OPD group (n=328).

    The analysis showed that the postoperative hospital stay in the LPD group was significantly less than that in the OPD group (median 15 days vs 16 days, P=0.
    02).

    There were no significant differences in the 90-day mortality rate and the incidence of serious postoperative complications between the two groups.

    The above results indicate that it is safe and feasible to perform LPD surgery by surgeons with rich clinical experience.

    Compared with OPD, LPD has shorter hospital stays and similar mortality and complication rates.

    Future research should focus on screening patient populations who can benefit from LPD.

    03Gastroenterology: Genetic and epigenetic characteristics of inflammatory bowel disease-related colorectal cancer.
    Recently, Gastroenterology published a study online showing that the dysregulation of WNT signaling pathway and increased OSMR signaling can promote inflammatory bowel disease-related colorectal cancer (IBD-CRC).
    ) The formation of mesenchymal subtypes.

    Article release screenshots.
    The study performed whole genome sequencing, single nucleotide polymorphism analysis, RNA sequencing, whole genome methylation analysis, and immunohistochemical detection on tumor tissues and matched normal tissue samples of 31 patients with IBD-CRC , It was found that IBD-CRC related to WNT signaling pathway is dominated by mesenchymal matrix subtypes.

    Compared with sporadic CRC (sCRC), AXIN2 and RNF43 (WNT inhibitor) levels were significantly down-regulated in IBD-CRCs, while HNT4A (WNT-mediated epithelial-mesenchymal transition inhibitor) had less chromosomal gain.

    PIGR and OSMR involved in mucosal immunity are dysregulated in IBD-CRCs due to epigenetic modification.

    Genome analysis showed that the 5'UTR non-coding mutations of TP53 were significantly enriched in IBD-CRCs, while the proportion of somatic mutations in APC and KRAS genes was lower than that in sCRCs.

    The above results indicate that IBD-CRCs have a unique tumorigenesis pathway compared to sCRCs, which may have an impact on the prognosis and treatment options of such patients.

    04New drug: Cadonilimab was approved to start a global phase III clinical trial for the first-line treatment of advanced cervical cancer.
    On April 28, 2021, Kangfang Bio announced that the National Center for Drug Evaluation (CDE) has agreed to start the world's first innovative tumor immunity independently developed by the evaluation company The new treatment drug Cadonilimab (PD-1/CTLA-4, development code: AK104) plus platinum-containing chemotherapy with or without bevacizumab, for the first-line treatment of persistent, recurrent or metastatic cervical cancer, randomized, double-blind, and comfort A dose-controlled phase III clinical study.

    This is the first phase III clinical study of dual immunotherapy for first-line cervical cancer in China.

    05 New drug: The first EGFR exon 20 insertion targeted drug TAK-788 received FDA priority review.
    Recently, Takeda announced that the U.
    S.
    Food and Drug Administration (FDA) has granted it a new drug under investigation for TAK-788 Apply for priority review qualification for the treatment of adult patients with metastatic NSCLC with positive EGFR exon 20 insertion.

    These patients had previously received platinum-containing chemotherapy.

    The press release states that TAK-788 is the first oral therapy specifically designed to selectively target the insertion of EGFR exon 20.

    Reference: [1] M.
    Wang, D.
    Li, R.
    Chen, et al.
    Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial.
    published on April 26, 2021.
    doi : https://doi.
    org/10.
    1016/S2468-1253(21)00054-6.
    [2]Yasuto Yoneshima, Satoshi Morita, Masahiko Ando, ​​et al.
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non -small cell lung cancer.
    published on April 26, 2021.
    doi: https://doi.
    org/10.
    1016/j.
    jtho.
    2021.
    03.
    027.
    [3]Kristiina Rajamäki, Aurora Taira, Riku Katainen, et al.
    Genetic and epigenetic characteristics of inflammatory bowel disease associated colorectal cancer.
    published on April 26, 2021.
    doi: https://doi.
    org/10.
    1053/j.
    gastro.
    2021.
    04.
    042.
    [4]https://mp.
    weixin.
    qq.
    com/s/Amdjt4W05XueuBX9hWtu1g[5]https://mp.
    weixin.
    qq.
    com/s/a3-c3iO_1YTdX9CTHT4gIg
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.